Sebastian Bauer

Professor / Chair

Universität Duisburg-Essen

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Medical Imaging Medical Imaging professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Sebastian Bauer is the Chair at the University of Duisburg-Essen in Germany. His research primarily focuses on innovative treatment approaches for various cancers, as evidenced by his recent publications on pexidartinib, CDK4/6 inhibition in chordoma, and strategies for managing gastrointestinal stromal tumors. He is committed to advancing the understanding of cancer therapies through clinical trials and real-world data analysis.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

Javier Martinez-Trufero

Associated Proffesor

Universidad de Murcia Facultad de Medicina

SPAIN

Sebastian Bauer

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

INSIGHT: A Phase III Trial of Ripretinib Versus Sunitinib in Patients with Advanced GIST with KIT Exon 11 and Exon 17/18 Mutations Who Were Previously Treated with Imatinib

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

Solitary Fibrous Tumor: A retrospective analysis of clinicopathological characteristics and palliative treatment of 67 cases

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial

Degradable Starch Microsphere Transarterial Chemoembolization as Salvage Therapy in Patients with Uveal Melanoma Liver Metastases.

Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Correction: Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability.

Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence.

Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST.

Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

Impact of CT and MRI in the diagnostic workup of malignant triton tumour—a monocentric analysis and review of the literature

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA.

Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.

Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification.

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies.

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma.

Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological Inpatients.

Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the United Kingdom.

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial.

Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.

New Prognostic Score (Essen Score) to Predict Postoperative Morbidity after Resection of Lung Metastases

Identification of novel pathogenic roles of BLZF1/ATF6 in tumorigenesis of gastrointestinal stromal tumor showing Golgi-localized mutant KIT

Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.

Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial.

Collaborators (16)

Javier Martinez-Trufero

Julius Keyl

Mathias Wilhelm

Emanuela Palmerini

Nicholas M. Bernthal

Stefan Kasper

Servet Bölükbas

Daniel Paul Zolg

Margaret von Mehren

Kim Jiyoon

John Healey

Johanna Falkenhorst

Carolina Larrain

Hans Gelderblom

Martin Schuler

Jean-Yves Blay

Make your next move.